drugset / Trial / NCT05360147

Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus

NCT05360147

Phase 3 Completed 30 enrolled Third Military Medical University
RandomizedParallel-groupSingle-blindTreatment

Summary

Patients with diabetes are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. In previous observational study, the investigators found that liraglutide can improve cognitive function in patients with T2DM through a metabolism-independent pathway. Here the investigators aim to further verify such effects through a randomized, controlled study.

Timeline

Start
2021-01-20
Primary completion
2021-04-20
Completion
2021-05-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.8 mg
Comparator Metformin Small molecule